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The zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1) is inhibited
by several classes of zinc-binders (sulfonamides, sulfamates, and
sulfamides) as well as by compounds which do not interact with
the metal ion (phenols, polyamines and coumarins). Here we
report a new class of potent CA inhibitors which bind the zinc
ion: the dithiocarbamates (DTCs). They coordinate to the zinc ion
from the enzyme active site in monodentate manner and establish
many favorable interactions with amino acid residues nearby.
Several low nanomolar CA I, II and IX inhibitors were detected.
Carbonic anhydrases (CAs, EC 4.2.1.1) are widespread metallo-
enzymes found in higher vertebrates including humans. 16 isozymes
have been characterised to date, many of which are involved in
critical physiological processes.1,2 They catalyse the following
reaction: CO2 + H2O = H
+ + HCO3
. In humans, CAs are
present in a large variety of tissues (gastrointestinal and
reproductive tract, nervous system, kidneys, lungs, skin and eyes).1–4
The different isozymes are localized in various parts of the cell
with CA I and CA II, important isozymes in normal cells,
being localised in the cytosol.1,2 Many of the CA isozymes are
important therapeutic targets with the potential to be inhibited
to treat a range of disorders.1,2 The classical CA inhibitors
(CAIs) are the primary sulfonamides, RSO2NH2 (and their
isosteres, the sulfamates/sulfamides) which are in clinical use
for more than 50 years as diuretics and systemically acting
antiglaucoma drugs.1,2 Apart from their use as diuretics and
antiglaucoma agents, recently it has emerged that they have
potential as anticonvulsant, antiobesity, anticancer, antipain
and antiinfective drugs.1,2 Critical barriers to the design of CA
inhibitors (CAIs) as therapeutic agents are related to the high
number of isoforms present in mammals (i.e., 16 CAs, of which 13
have catalytic activity), their diffuse localization in many
tissues/organs, and the lack of isozyme selectivity of many of the
presently available inhibitors of the sulfonamide/sulfamate type.3–7
However, crucial advances have been ultimately made in this field,
with several novel chemotypes reported to behave as potent
CAIs,3,4,7–10 such as the coumarins and thiocoumarins,3,4 the
polyamines,6 etc.
There are two main CA inhibition mechanisms: sulfonamides
and their bioisosteres coordinate directly to the metal ion from the
enzyme active site whereas phenols, polyamines and coumarins/
thiocoumarins do not directly interact with the zinc ion.1–4
All the zinc binders known so far (organic compounds)
coordinate monodentately to the zinc ion through a nitrogen
atom from the zinc-binding group (ZBG),7–10 whereas few
bidentate inhibitors have been discovered, such as a thiomalthol
anlogue (HOPTO)11 and N-hydroxyurea12 which were shown to
coordinate bidentately to the Zn(II) ion from the enzyme active site.
Dithiocarbamates (DTCs) are well knownmetal complexing agents
and they also possess interesting biomedical and agricultural
applications.13,14 However few studies investigated their inter-
actions with metalloenzymes.15 One such work has investigated
the inhibition of N,N-diethyl-DTC with bovine CA.16 By using
Co(II)-substituted CA, Morpurgo et al.16 showed that the
inhibitor does not extrude the metal ion from the enzyme active
site and that it binds to it in a trigonal-bipyramidal geometry of
the Co(II) ion. No other DTCs were subsequently investigated
for their interaction with CAs till our group reported that
trithiocarbonate, which contains a new ZBG, (CS2
) as well
as diethyl-DTC, inhibit several CA isoforms in the low micro-
molar or submicromolar range.17 Here we extend those findings,
showing that a wide range of DTCs incorporating various
aliphatic and/or aromatic moieties at the nitrogen atom, act as
low nanomolar and even subnanomolar CAIs. We elucidate the
mechanism of action of this new class of potent CAIs, by
reporting the X-ray crystal structures for the adducts of two
DTCs in complex with the human (h) isoform CA II. The
investigated DTCs 1–9 were prepared as described in the ESIw,
by reacting amines with CS2 in the presence of sodium
hydroxide.
Three CA isoforms were included in this study (Table 1): the
cytosolic CA I and II and the transmembrane, tumor-associated
CA IX. CA I and II are the most abundant CAs in the body being
also drug targets.1,2 CA IX is an anticancer drug target.4,18,19
Data of Table 1 show the following interesting findings.
Against the slow cytosolic isoform hCA I the activity range
of DTCs 1–9 was between 0.97 nM–1.84 mM. The simple
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dimethyl-DTC was a moderate hCA I inhibitor (KI of 0.7 mM)
and this trend was observed also for its simple congeners
incorporating two Et or two n-Pr moieties (2 and 3) which
showed inhibition constants in the range of 0.79–1.84 mM.
A further elongation of the aliphatic chain led to very strong
CAIs, with the n-Bu derivative 4 being a nanomolar and the
iso-butyl isomer 5 a subnanomolar hCA I inhibitor (Table 1).
The remaining derivatives 6–9, possessing various R moieties
substituting the nitrogen atom showed effective hCA I inhibitory
activity, with KIs in the range of 39.6–157 nM, all these
compounds being better CAIs compared to the clinically used
sulfonamide acetazolamide 10 (5-acetamido-1,3,4-thiadiazole-2-
sulfonamide).1
For the rapid isoform hCA II a different inhibition pattern
has been observed. Thus, the simplest derivatives 1 and 2
behaved as ineffective CAIs, with KIs in the range of 3.1–6.9 mM,
whereas all the remaining DTCs investigated here showed highly
effective such properties, with KIs in the range of 0.95–55.5 nM.
The most effective inhibitor was again the di-isobutyl-DTC 5.
The tumor-associated extracellular isoform hCA IX was
also inhibited by all these compounds, with KIs in the range of
4.5–1413 nM (Table 1). The simple aliphatic derivatives 1 and 2,
as well as the piperidine derivative 9 were ineffective CAIs
(KIs of 714–1413 nM) whereas the remaining compounds showed
a highly enhanced efficacy (KIs in the range of 4.5–53.8 nM),
being more effective compared to the sulfonamide 10 as inhibitors
of hCA IX.
These data prove that small structural changes in the
molecule of this new class of CAIs lead to dramatic changes
of the enzyme inhibitory activity, which is an interesting
finding when a new class of inhibitors is reported. In order
to rationalize these findings at the molecular level, we resolved
the X-ray crystal structure for the adducts of two of these
DTCs bound to hCA II.21
The X-ray crystal structures of CA II complexed with 8 and 9
have been determined (Fig. 1) to 1.5 A˚ resolution, using a
protocol as previously described by us (refer to supplementary
text and Table S1 (ESIw) for experimental details).9 The two
compounds were well ordered and refined with occupancies of
0.85 and 1.00 and B-factors that were comparable to the
solvent within the active site. The hydrophobic non-planar
compounds are buried deep into the active site, displacing the
catalytic zinc-bound solvent, such that one of the sulfurs binds
directly to the zinc atom of hCA II (distance B2.3 A˚). Hence
the overall Zn (3N from coordinating histidines, and 1S
inhibitor ligand) coordination can be described as a distorted
tetrahedron. Both compounds protrude out of the active site
with their tail groups stabilized predominantly by hydrophobic
residues. Compound 8 exhibits van der Waals interactions with
the side chains of Asn62, His64, Glu92, His94, Val121, Phe131,
Leu198, Thr200 and Pro202 (Fig. 1A and 2 (green)), with an
average B-factor of 20.0 A˚2 and occupancy of 0.85 (Table S1,
ESIw). Approximately 330 A˚2 (92%) of the surface area of the
compound is buried. Compound 9, the largest in size among the
three compounds, possesses a nitrogen atom which hydrogen
bonds with a surrounding water molecule and to the side chains
of Asn67 and Gln92, and as a consequence buries B360 A˚2
(82.3%) of its surface area. The hydrophobic cyclohexane ring
at the distal end of the compound protrudes outwards from the
active site and is additionally stabilized by the side chains of
Phe131, Leu198 and Pro202 (Fig. 1B and 2 (pink)).
In conclusion we report here that the N,N-disubstituted
dithiocarbamates inhibit various CA isoforms (established
drug targets for a variety of disorders) with efficiencies
between the subnanomolar to the micromolar, depending on
the nature of the aliphatic/aromatic groups present in their
molecules. By means of high resolution X-ray crystallography
we also explain the good efficacy of this new class of CAIs to
inhibit various isoforms. Due to their simple chemical nature,
ease of preparation and good water solubility, DTCs may
show various applications in fields in which CA inhibition is
necessary.
This research was financed by an FP7 EU project (Metoxia)
and a grant from the NIH GM 25154.
Table 1 CA inhibition data with DTCs 1–9 (R1R2NCS2
Na+) and
acetazolamide 10 (as standard inhibitor) against the cytosolic isoforms
hCA I and II and transmembrane, tumor-associated one hCA IX
DTC, (R1,R2 groups)
KI (hCA I)/
nM
KI (hCA II)/
nM
KI (hCA IX)/
nM
1 (Me, Me) 699 6910 714
2 (Et, Et) 790 3100 1413
3 (nPr, nPr) 1838 55.5 53.8
4 (nBu, nBu) 43.1 50.9 50.3
5 (iBu, iBu) 0.97 0.95 4.5
6 (Et, nBu) 157 27.8 25.9
7 (Me, Ph) 39.6 21.5 28.2
8 (Me, PhCH2) 69.9 25.4 53.0
9 (NC(Ph)C(CH2CH2)2 48.4 40.8 757
10 (acetazolamide) 250 12 25
Errors were in the range of 5–10% of the reported data (from
3 different assays, data not shown) by a stopped-flow assay.20
Fig. 1 Electron densities for X-ray crystal structures of adducts of
DTCs 8 (A) and 9 (B) with hCA II.
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